Clinical efficacy and safety of the combination of an intracoronary tirofiban infusion plus percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction
10.3760/cma.j.issn.0254-9026.2011.05.019
- VernacularTitle:冠状动脉介入术联合冠状动脉腔内注入替罗非班治疗急性ST段抬高性心肌梗死的临床观察
- Author:
Zichao WANG
;
Yi HAO
;
Wenxiang ZHANG
;
Yanhong LI
- Publication Type:Journal Article
- Keywords:
Platelet glycoprotein GPⅡb-Ⅲa complex;
Myocardial infarction;
Radiology interventional
- From:
Chinese Journal of Geriatrics
2011;30(5):416-419
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical efficacy and safety of the combination of intracoronary tirofiban infusion(ICTI) plus percutaneous coronary intervention(PCI) in patients with acute ST-elevation myocardial infarction (STEAMI). Methods The 128 cases with STEAMI were enrolled in this study. They were randomly divided into trial group and control group. The 10 μg/kg tirofiban were infused into the infarct related artery (IRA) within 5 minutes through the cather after coronary angiography in trial group (n=64). Normal saline in matched dose was infused into IRA after coronary angiography in control group (n=64). The coronary thrombosis and revascularization status were assessed within 10 minutes after injection. Postoperative bleeding complications were observed in all cases. Adverse cardiovascular events and cardiac function were followed up within 1 month in all cases. Results There were 33 cases whose thrombus burden was reduced within 10 minutes after the infusion of tirofiban in trial group, including 26 cases of thrombolysis in myocardial infarction (TIMI) ≥1. There were 6 cases whose thrombus burden was reduced within 10 minutes after the infusion of normal saline in control group, including 3 cases TIMI ≥ 1. The coronary thrombosis and revascularization status were better in trial group rather than in control group (P＜0.01). Adverse cardiovascular events occurred in 5 cases within 1 month, including 2 cases in trial group and 3 cases in control group (P＞0.05). New York heart association functional class and ejection fraction values were better in trial group rather than in control group within 1 month (P＜0.05). Postoperative bleeding complications occurred in 14 cases by TIMI criteria , including severe and mild bleeding in 2 cases in trial group and 1 cases in control group (P＞0.05), but no significant bleeding occurred in 8 cases in trial group and in 3 cases in control group (P＜0.01). Conclusions The combination of intracoronary infusion of tirofiban plus PCI is effective and safe for thrombolysis and revascularization in IRA in patients with STEAMI.
